Cargando…

ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment

Detalles Bibliográficos
Autor principal:	Aragon-Ching, Jeanny B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Invited Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933959/ https://www.ncbi.nlm.nih.gov/pubmed/35645046 http://dx.doi.org/10.4103/aja202230

Ejemplares similares

Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2020)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Vitamin D in prostate cancer
por: Trump, Donald L, et al.
Publicado: (2018)

The path forward in prostate cancer therapeutics
por: Aragon-Ching, Jeanny B, et al.
Publicado: (2018)

Role of chemotherapy in prostate cancer
por: Nader, Rita, et al.
Publicado: (2018)

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones
por: Schally, Andrew V, et al.
Publicado: (2015)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

How to make a human germ cell
por: Cooke, Paul S, et al.
Publicado: (2015)

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2019)

Prostate cancer screening: and yet it moves!
por: Kwiatkowski, Maciej, et al.
Publicado: (2015)

To screen or not to screen: the prostate cancer dilemma
por: Stone, Nelson N, et al.
Publicado: (2015)

External beam radiotherapy for localized prostate cancer
por: Yilmaz, Hasan, et al.
Publicado: (2015)

Testosterone replacement therapy and the risk of prostate cancer
por: Warburton, Daniel, et al.
Publicado: (2015)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Current and emerging trends in prostate cancer immunotherapy
por: Schatz, Adam, et al.
Publicado: (2019)

Highlights—Does Methylation Make the Parent? A First Dive into the Genetics of Social Beetles
por: Venton, Danielle
Publicado: (2015)

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Lohiya, Vipin, et al.
Publicado: (2016)

Androgen receptor functions in prostate cancer development and progression
por: Balk, Steven P
Publicado: (2014)

Prevention of erectile dysfunction after radiotherapy for prostate cancer
por: Faiena, Izak, et al.
Publicado: (2014)

Next generation patient-derived prostate cancer xenograft models
por: Lin, Dong, et al.
Publicado: (2014)

Long-term survival of participants in the prostate cancer prevention trial
por: Silberstein, Jonathan L, et al.
Publicado: (2014)

Management of localized prostate cancer: the pendulum swings (back to the middle)
por: Vuong, Winston, et al.
Publicado: (2014)

Lipogenic metabolism: a viable target for prostate cancer treatment?
por: Liang, Mengmeng, et al.
Publicado: (2014)

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity
por: Mendonca, Janet, et al.
Publicado: (2015)

HOXB13 and other high penetrant genes for prostate cancer
por: Pilie, Patrick G, et al.
Publicado: (2016)

Re: Long-term survival of participants in the Prostate Cancer Prevention Trial
por: Thompson, Ian M, et al.
Publicado: (2014)

Morbidity and psychological impact of prostate biopsy: the future calls for a change
por: Minervini, Andrea, et al.
Publicado: (2014)

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer
por: Petrovics, Gyorgy, et al.
Publicado: (2014)

Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification
por: Chiang, Yan Ting, et al.
Publicado: (2014)

Tools to identify the men with prostate cancer most appropriate for active surveillance?
por: Getzenberg, Robert H
Publicado: (2014)

Robotic radical prostatectomy in high-risk prostate cancer: current perspectives
por: Canda, Abdullah Erdem, et al.
Publicado: (2015)

Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods
por: Moyad, Mark A
Publicado: (2015)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities
por: Yu, Eun-mi, et al.
Publicado: (2023)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3o78icoi69u5vtq25pn6ac2n4k